KR20210016398A - 암 치료에 사용하기 위한 ccr5 억제제 - Google Patents

암 치료에 사용하기 위한 ccr5 억제제 Download PDF

Info

Publication number
KR20210016398A
KR20210016398A KR1020207037076A KR20207037076A KR20210016398A KR 20210016398 A KR20210016398 A KR 20210016398A KR 1020207037076 A KR1020207037076 A KR 1020207037076A KR 20207037076 A KR20207037076 A KR 20207037076A KR 20210016398 A KR20210016398 A KR 20210016398A
Authority
KR
South Korea
Prior art keywords
seq
cancer
ccr5
ccr5 inhibitor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207037076A
Other languages
English (en)
Korean (ko)
Inventor
올리버 하르틀레이
로빈 에와르트 오포르드
Original Assignee
오리온 바이오테크놀로지 스윗졀랜드 에스아에흐엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리온 바이오테크놀로지 스윗졀랜드 에스아에흐엘 filed Critical 오리온 바이오테크놀로지 스윗졀랜드 에스아에흐엘
Publication of KR20210016398A publication Critical patent/KR20210016398A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020207037076A 2018-05-28 2019-05-24 암 치료에 사용하기 위한 ccr5 억제제 Withdrawn KR20210016398A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677114P 2018-05-28 2018-05-28
US62/677,114 2018-05-28
US201962792600P 2019-01-15 2019-01-15
US62/792,600 2019-01-15
PCT/IB2019/054350 WO2019229616A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
KR20210016398A true KR20210016398A (ko) 2021-02-15

Family

ID=67480241

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207037076A Withdrawn KR20210016398A (ko) 2018-05-28 2019-05-24 암 치료에 사용하기 위한 ccr5 억제제

Country Status (11)

Country Link
US (1) US20210205411A1 (https=)
EP (1) EP3813870B1 (https=)
JP (2) JP7319020B2 (https=)
KR (1) KR20210016398A (https=)
CN (1) CN112469429B (https=)
AU (1) AU2019276939A1 (https=)
BR (1) BR112020024328A2 (https=)
CA (1) CA3101556A1 (https=)
MX (1) MX2020012782A (https=)
WO (1) WO2019229616A1 (https=)
ZA (1) ZA202007955B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019405A2 (pt) * 2019-04-01 2021-11-30 Cytodyn Inc Agentes anti-ccr5 e métodos de tratamento que bloqueiam a metástase do câncer ou aumentam a morte celular induzida pela quimioterapia prejudicial ao dna
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2024146707A1 (en) * 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) * 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
ES2800316T3 (es) * 2011-06-13 2020-12-29 Tla Targeted Immunotherapies Ab Tratamiento del cáncer
JP6518585B2 (ja) * 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3212228B1 (en) * 2014-10-27 2025-12-03 Ruprecht-Karls-Universität Heidelberg Maraviroc alone or in combination therapy for the treatment of cancer
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Also Published As

Publication number Publication date
CN112469429A (zh) 2021-03-09
JP2021525770A (ja) 2021-09-27
CA3101556A1 (en) 2019-12-05
EP3813870A1 (en) 2021-05-05
EP3813870C0 (en) 2023-11-15
BR112020024328A2 (pt) 2021-02-23
WO2019229616A1 (en) 2019-12-05
MX2020012782A (es) 2021-04-28
EP3813870B1 (en) 2023-11-15
ZA202007955B (en) 2022-06-29
CN112469429B (zh) 2025-02-14
JP7319020B2 (ja) 2023-08-01
JP2023134704A (ja) 2023-09-27
US20210205411A1 (en) 2021-07-08
AU2019276939A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US12043664B2 (en) Methods for treating vascular leak syndrome and cancer
KR20210016398A (ko) 암 치료에 사용하기 위한 ccr5 억제제
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
CN110996952A (zh) 用于治疗癌症的方法
US11602554B2 (en) P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
CN113474048A (zh) 用于癌症治疗的组合物和方法
BR112020014574A2 (pt) Composições e métodos para o tratamento do câncer
US20240417473A1 (en) Lag-3 antagonist therapy for hematological cancer
US20210196744A1 (en) Compositions for cancer therapy and methods
US20240000883A1 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
KR20200016877A (ko) 표적 치료제를 포함하는 병용 요법
CA3230917A1 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
HK40048943A (en) Ccr5 inhibitor for use in treating cancer
US20250114331A1 (en) Concurrent targeting of oncogenic pathways to enhance chemotherapy and immunotherapy
CN102036680A (zh) 促肾上腺皮质激素释放因子用于治疗癌症的用途
HK40050404A (en) Compositions and methods for cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220523

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20241204

WITB Written withdrawal of application